Skip to content

A Randomized Controlled Trial to Evaluate the Efficacy of Acupuncture Versus Aromatherapy as Treatments to Lessen Nausea, Vomiting and Anxiety Associated With Adriamycin and Cytoxan

A Randomized Controlled Trial to Evaluate the Efficacy of Acupuncture Versus Aromatherapy as Treatments to Lessen Nausea, Vomiting and Anxiety Associated With Adriamycin and Cytoxan

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04116697
Enrollment
26
Registered
2019-10-07
Start date
2019-10-23
Completion date
2024-10-01
Last updated
2025-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Nausea, Vomiting

Brief summary

The overall goal of this study is to explore the effectiveness of using acupuncture versus aromatherapy, in conjunction with standard of care anti-emetics, to decrease chemotherapy induced nausea, vomiting, and anxiety in breast cancer patients undergoing Adriamycin and Cytoxan. This study also aims to determine if aromatherapy and anti-emetics is more effective than acupuncture and anti-emetics in treating nausea, vomiting, and anxiety in patients receiving Adriamycin and Cytoxan and if acupuncture and anti-emetics is more effective than aromatherapy and anti-emetics in treating nausea, vomiting, and anxiety in patients receiving Adriamycin and Cytoxan.

Interventions

OTHERAcupuncture

Acupuncture is a form of alternative medicine in which thin needles are inserted into the body.

OTHERAromatherapy

Aromatherapy is a form of alternative medicine in which you will inhale aromatic plant extracts and essential oils.

Sponsors

Englewood Hospital and Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

i) Inclusion * At least 18 years of age on the day of signing informed consent * Patient has a diagnosis of breast cancer * Patient is planned to start Adriamycin and Cytoxan chemotherapy ii) Exclusion * Patients who are unable to adhere to the protocol or treatment schedule * Patients who have a concurrent illness or take medication that induces nausea independent of chemotherapy * Patients undergoing radiotherapy or hormone therapy during chemotherapy treatments * Patients who have a sensitive and/or poor sense of smell * Patients who are allergic to essential oils, specifically peppermint, ginger, and/or lavender * Patients who are already using essential oils or acupuncture for symptom management and are unwilling to stop while participating in this study * Patients who are afraid of or unwilling to receive acupuncture stimulation * Patients who are allergic to stainless steel needles * Thrombocytopenia (Platelets \< 20,000) * Patients who have received aromatherapy and/or acupuncture treatment within 1 week of starting treatment on this study

Design outcomes

Primary

MeasureTime frameDescription
Improvement in Nausea45 daysPatients will complete an Edmonton Symptom Assessment Scale. Patients will rate their level of nausea from 0-10 with 10 being the worst possible nausea. Patients will also complete a symptom diary where they will track their level of nausea and how often they are nauseous. Patients will also complete an Anti-Emetic Diary which will track how often they are taking their anti-emetic medications to combat nausea.
improvement in anxiety45 daysPatients will complete an Edmonton Symptom Assessment Scale. Patients will rate their level of anxiety from 0-10 with 10 being the worst possible anxiety. Patients will also complete a symptom diary where they will track their level of anxiety and how often they are anxious.
improvement in vomiting45 daysPatients will complete a symptom diary where they will track how often they vomit. Patients will also complete an Anti-Emetic Diary which will track how often they are taking their anti-emetic medications to combat vomiting.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026